NPO Petrovax Pharm will increase the manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms (tablets and suppositories) of original local pharmaceuticals.
In October 2016, the Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor), following the audit, approved the issue of a GMP certificate for NPO Petrovax Pharm to manufacture the veterinary medicines AZOXIVET and Vetolaza. The Company has taken the lead as the first Russian manufacturer of veterinary medicines to comply with the GMP standards approved in Russia.
In August 2016, NPO Petrovax Pharm delivered 1.5 m doses of its Grippol® Plus anti-influenza vaccine to the Republic of Kazakhstan. The shipments were made under the government's procurement programme providing for the purchase of medicines and healthcare products from the SK-Pharmacy's uniform distributor in the scope of the guaranteed free medical care plan.
The Republic of Kazakhstan will use the Russian Grippol® Plus for the purposes of anti-flu vaccination in 2016.
Petrovax Pharm has been authorised by the Ministry of Health to manufacture Grippol® Plus, Russian flu vaccine, using flu antigens produced by the Saint Petersburg Research Institute for Vaccines and Sera of the Federal Biomedical Agency of Russia. The two companies’ joint project is part of their long-term strategic partnership agreement signed in 2015 to develop, produce and implement advanced Russian vaccines in the national healthcare system.
During an official ceremony held on 3 December 2015, NPO Petrovax Pharm was handed the Russian Nanotechnology Product Award, which confirmed the quality, effectiveness and safety of the Grippol Plus flu vaccine, as well as its status of a nanotechnology product. As of today, Grippol Plus is the first and only medicine to receive this prestigious award.
As of 08 December 2011, the childhood vaccination with Grippol® Plus is nearing completion with over 11.9 million children vaccinated (99.7% coverage).
NPO Petrovax Pharm, a leader among Russian pharmaceutical developers and manufacturers of innovative medicinal products, is proud to announce the arrival of Grippol® Plus vaccine in No 5 ampoules.
In early October this year, with support of the Tula Region government, Tula initiated the complex programme "Healthy Child". The programme is aimed at lowering the incidence of influenza and acute respiratory viral infections among children. Its main objectives include raising influenza immunisation awareness among children and their parents and improving the quality of training for infectious disease prevention specialists.
The cooperation of Pfizer and NPO Petrovax Pharm will help further develop Russian manufacturers’ technologies and increase the availability of preventive vaccinations against dangerous diseases for Russian children.
Moscow, 10 March 2011: Today Pfizer announced an agreement with Russian biopharmaceutical company Petrovax Pharm to manufacture Pfizer’s innovative pneumococcal vaccine at Petrovax’s cutting-edge facilities in the Moscow Region.
Petrovax Group registers the Polyoxidonium®-vet solution.
Petrovax Group, a Russian-based developer and manufacturer of innovative medicines and vaccines, has registered Polyoxidonium®-vet solution (Registration Certificate 32-3-8.0-0058 No. PVR-3-8.0/02643) for veterinary use.
Polyoxidonium®, an effective and safe immunomodulator with a combination of pharmacological properties, now has new storage temperature requirements.
This unique drug, developed and manufactured by Petrovax Group, has been successfully used in clinical practice for 15 years.